GB1006258A - Improvements in rendering less soluble or less dispersable in an aqueous liquid, a proteinaceous substance - Google Patents

Improvements in rendering less soluble or less dispersable in an aqueous liquid, a proteinaceous substance

Info

Publication number
GB1006258A
GB1006258A GB48051/62A GB4805162A GB1006258A GB 1006258 A GB1006258 A GB 1006258A GB 48051/62 A GB48051/62 A GB 48051/62A GB 4805162 A GB4805162 A GB 4805162A GB 1006258 A GB1006258 A GB 1006258A
Authority
GB
United Kingdom
Prior art keywords
polyethylene glycol
proteinaceous substance
proteins
toxin
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB48051/62A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South African Inventions Development Corp
Original Assignee
South African Inventions Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South African Inventions Development Corp filed Critical South African Inventions Development Corp
Publication of GB1006258A publication Critical patent/GB1006258A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0039—Post treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/816—Enzyme separation or purification by solubility
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A proteinaceous substance is rendered less soluble or less dispersible in an aqueous liquid by adding to said liquid with the proteinaceous substance dissolved or colloidally dispersed therein, polyethylene glycol having a molecular weight of at least 300 to precipitate at least some of said proteinaceous substance. The proteins may be mixed and fractional precipitation of the proteins is brought about by the addition of the polyethylene glycol. Aqueous polyethylene glycol of suitable concentration may be used for selective elution of precipitated protein fractions. The average molecular weight of the polyethylene glycol may be up to 100,000. The temperature may be from 0 DEG to 40 DEG C. and the process may be used in conjunction with pH control and inorganic salt precipitation. Examples relate to the fractionation of human blood plasma and the purification of Clostridium Novyi toxin, Botulinus Toxin type D, Tetanus anti-toxin, pancreatic desoxyribonuclease, fibrinogen and gamma globulin. In general, the process is applicable to the separation, isolation and purification of plasma proteins, anti-toxins, bacterial toxins, viruses, nucleic acid and enzymes.ALSO:A proteinaceous substance is rendered less soluble or less dispersable in an aqueous liquid by adding to said liquid with the proteinaceous substance dissolved or colloidally dispersed therein, polyethylene glycol having a molecular weight of at least 300 to precipitate at least some of said proteinaceous substance. The proteins may be mixed and fractional precipitation of the proteins is brought about by the addition of the polyethylene glycol. Aqueous polyethylene glycol of suitable concentration may be used for selective elution of precipitated protein fractions. The average molecular weight of the polyethylene glycol may be up to 100,000. The temperature may be from 0 DEG C to 40 DEG C. and the process may be used in conjunction with pH control and inorganic salt precipitation. Examples relate to the fractionation of human blood plasma and the purification of Clostridium Novyi toxin, Botulinus Toxin type D, Tetanus anti-toxin, pancreatic desoxyribonuclease, fibrinogen and gamma-globulin. In general, the process is applicable to the separation, isolation and purification of plasma proteins, antitoxins, bacterial toxins, viruses, nucleic acid and enzymes.
GB48051/62A 1962-01-03 1962-12-19 Improvements in rendering less soluble or less dispersable in an aqueous liquid, a proteinaceous substance Expired GB1006258A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA6234 1962-01-03

Publications (1)

Publication Number Publication Date
GB1006258A true GB1006258A (en) 1965-09-29

Family

ID=25560644

Family Applications (1)

Application Number Title Priority Date Filing Date
GB48051/62A Expired GB1006258A (en) 1962-01-03 1962-12-19 Improvements in rendering less soluble or less dispersable in an aqueous liquid, a proteinaceous substance

Country Status (3)

Country Link
US (1) US3415804A (en)
GB (1) GB1006258A (en)
NL (1) NL286954A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1767285A1 (en) * 1967-05-01 1971-08-19 Baxter Laboratories Inc Process for the production of a concentrate of the stable antihamophilic factor with high efficiency
FR2413363A1 (en) * 1977-12-27 1979-07-27 Sclavo Inst Sieroterapeut METHOD FOR THE PREPARATION OF HUMAN CHORIONIC SOMATOMAMMOTROPIN
EP0270025A3 (en) * 1986-12-02 1989-05-10 Schwab & Co. Ges.M.B.H. Process for the preparation of an intravenously administrable immunoglobulin stable in the liquid phase

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502545A (en) * 1968-09-27 1970-03-24 Monsanto Co Process for the separation of water-soluble polymeric materials from unbound protein or peptide using semiporous gel
CA940070A (en) * 1968-12-23 1974-01-15 Jim S. Berry Stabilized aqueous enzyme composition
BR6915288D0 (en) * 1969-03-15 1973-02-08 Bayer Ag PROCESS FOR THE PURIFICATION OF SOLUTIONS OF THE FOOT-AND-Mouth Disease VIRUS
SE348942B (en) * 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3869436A (en) * 1971-06-01 1975-03-04 Statens Bakteriologiska Lab Method for fractionating plasma proteins using peg and ion-exchangers
US3880989A (en) * 1973-01-30 1975-04-29 Baxter Laboratories Inc Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US4000121A (en) * 1973-01-30 1976-12-28 Baxter Travenol Laboratories, Inc. Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer
NL7404590A (en) * 1974-04-03 1975-10-07 Stichting Rega V Z W METHOD OF REACTIVATING INTERFERON.
FR2267115B1 (en) * 1974-04-12 1977-11-10 Merieux Inst
US4025500A (en) * 1974-06-06 1977-05-24 Baxter Laboratories, Inc. Preparation of albumin by fractionation of blood plasma or serum
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US3995019A (en) * 1975-03-04 1976-11-30 Baxter Travenol Laboratories, Inc. Diagnostic reagent system
CA1101332A (en) * 1976-01-30 1981-05-19 Edward Shanbrom Simplified method for preparation of high yield, high purity factor viii concentrate
DE2607766C3 (en) * 1976-02-26 1978-12-07 Behringwerke Ag, 3550 Marburg Process for the production of carrier-bound biologically active substances
DK139056B (en) * 1976-04-06 1978-12-11 Nordisk Insulinlab Method for recovering immunoglobulin suitable for intravenous administration.
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
DK144731C (en) * 1976-07-30 1982-10-18 Nordisk Insulinlab PROCEDURE FOR INSULATING PROTEIN HORMONES DERIVED FROM HUMAN HYPPHYPHYSE TISSUE
JPS6016406B2 (en) * 1976-08-06 1985-04-25 マイヤ−、ル−イス、コ−バル Method for producing intravenously administrable gamma globulin and gamma globulin prepared thereby
US4124576A (en) * 1976-12-03 1978-11-07 Coval M L Method of producing intravenously injectable gamma globulin
DK25877A (en) * 1977-01-21 1978-08-15 Nordisk Insulinlab PROCEDURE FOR EXTRACTING PURE ALBUMIN FROM BLOOD PLASMA
US4197238A (en) * 1977-04-12 1980-04-08 The Green Cross Corporation Method of preparation of human albumin using polyethylene glycol
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
DE2750045A1 (en) * 1977-11-09 1979-05-10 Behringwerke Ag METHOD FOR REMOVING DETERGENTS FROM VIRUS ANTIGENS SUSPENSIONS
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
US4164496A (en) * 1978-08-23 1979-08-14 American National Red Cross Preparation of albumin using PEG and EDTA
AT359641B (en) * 1978-09-19 1980-11-25 Immuno Ag METHOD FOR PRODUCING AN INTRAVENOUS ADMINISTRABLE ANTIBODY-CONTAINING IMMUNOGLOBULIN PREPARATE
JPS5610119A (en) * 1979-07-05 1981-02-02 Alpha Therapeutic Corp Manufacture of b type hepatitis infection preventive vaccine
JPS5625114A (en) * 1979-08-07 1981-03-10 Green Cross Corp:The Preparation of human gamma globulin
DE2951412A1 (en) * 1979-12-20 1981-07-16 South African Inventions Development Corp., Pretoria, Transvaal Immunity sample prodn. - by removing lipoid from egg yolk, and mixing with a polymer and precipitant to impart non-dispersibility to antibody
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4379087A (en) * 1982-06-17 1983-04-05 Cutter Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4439421A (en) * 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS59157017A (en) * 1983-02-25 1984-09-06 Green Cross Corp:The Gamma-globulin preparation for intravenous injection
US4615885A (en) * 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4835257A (en) * 1984-07-07 1989-05-30 Armour Pharma Gmbh Process for preparing gamma globulin suitable for intravenous administration using peg and a citrate buffer
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4728613A (en) * 1985-09-04 1988-03-01 Miles Laboratories, Inc. Method for the recovery of extracellular enzymes from whole fermentation beer
US4684723A (en) * 1985-09-11 1987-08-04 Miles Laboratories, Inc. Method of separating proteins from aqueous solutions
US4697003A (en) * 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5139943A (en) * 1989-06-13 1992-08-18 Genencor International, Inc. Processes for the recovery of microbially produced chymosin
US5151358A (en) * 1989-06-13 1992-09-29 Genencor International, Inc. Processes for the recovery of naturally produced chymosin
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5290474A (en) * 1990-10-05 1994-03-01 Genencor International, Inc. Detergent composition for treating cotton-containing fabrics containing a surfactant and a cellulase composition containing endolucanase III from trichoderma ssp
CA2093422C (en) * 1990-10-05 2001-04-03 Detergent compositions containing cellulase compositions deficient in cbh i type components
JP3145696B2 (en) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 Method for producing secretory immunoglobulin A preparation
US5328841A (en) * 1990-10-05 1994-07-12 Genencor International, Inc. Methods for isolating EG III cellulase component and EG III cellulase in polyethylene glycol using inorganic salt and polyethylene glycol
US20060003654A1 (en) * 2004-06-30 2006-01-05 Lostocco Michael R Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers
EP3057987B1 (en) 2013-10-18 2020-12-23 Novasep Process Purification of proteins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1767285A1 (en) * 1967-05-01 1971-08-19 Baxter Laboratories Inc Process for the production of a concentrate of the stable antihamophilic factor with high efficiency
FR2413363A1 (en) * 1977-12-27 1979-07-27 Sclavo Inst Sieroterapeut METHOD FOR THE PREPARATION OF HUMAN CHORIONIC SOMATOMAMMOTROPIN
EP0270025A3 (en) * 1986-12-02 1989-05-10 Schwab & Co. Ges.M.B.H. Process for the preparation of an intravenously administrable immunoglobulin stable in the liquid phase
US4880913A (en) * 1986-12-02 1989-11-14 Schwab & Co. Ges.M.B.H. Process for the preparation of an immunoglobulin which can be administered intravenously and is stable in liquid form

Also Published As

Publication number Publication date
NL286954A (en)
US3415804A (en) 1968-12-10

Similar Documents

Publication Publication Date Title
GB1006258A (en) Improvements in rendering less soluble or less dispersable in an aqueous liquid, a proteinaceous substance
Abney et al. Candidate for immunoglobulin D present on murine B lymphocytes
Eigel et al. Plasmin-mediated proteolysis of casein in bovine milk.
Kozaki et al. Purification and some properties of progenitor toxins of Clostridium botulinum type B
Alper et al. The relationship of glycine-rich ß-glycoprotein to factor B in the properdin system and to the Cobra factor-binding protein of human serum
Miyazaki et al. Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties
Jenkins et al. Purification of the soluble hemolysins of Listeria monocytogenes
KR910002467A (en) Polyclonal immunoglobulin preparation for intravenous administration containing lgM and preparation method thereof
FI854395A (en) SV40 EXPRESSIONS VECTOR INNEHAOLLANDE HBXAG-ANTIGEN SOM EXPRESSIONSMARKERING.
Beeby et al. The action of rennin on casein The disruption of the k-casein complex
US3227626A (en) Plasminogen heat sterilization
Esteves et al. Antigenic similarities among mammalian immunoglobulins
Christensen Protamine purification of streptokinase and effect of pH and temperature on reversible inactivation
Hill Purification and properties of streptococcal hyaluronate lyase
Zolli Jr et al. Purification and characterization of staphylocoagulase
Lachmann et al. Solubilization and characterization of surface antigenic components of Erysipelothrix rhusiopathiae T28
Dimond et al. Purification and characterization of a staphylococcal epidermolytic toxin
Yamamoto Studies on Sensitive Groups of Crystalline Bacterial α-Amylase
US2175090A (en) Purification of antibody compositions
Ullah et al. Mycoplasma phosphoenolpyruvate-dependent sugar phosphotransferase system: purification and characterization of the phosphocarrier protein
Turner Purification and characterization of an immunologically distinct delta-hemolysin from a canine strain of Staphylococcus aureus
Madinaveitia Studies on diffusing factors. III
Butler Studies on the preparation and isoelectric point of staphylococcal α-haemolysin
Hanson et al. Isolation of immunologically active fragments of normal human γ-globulin after tryptic degradation
Zikán Interactions of pig Fabμ and Fabα fragments with protein a from Staphylococcus aureus